Non Invasive Haemodynamics in Neuraxial Anaesthesia Hypotension
NCT ID: NCT03653442
Last Updated: 2020-03-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
55 participants
OBSERVATIONAL
2018-06-10
2020-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Predictive Hemodynamic Monitoring During Elective Cesarean Section
NCT06729827
Intensive Versus Standard Treatment for Spinal Anesthesia-induced Hypotension on Maternal Hemodynamics
NCT06151496
Maternal Hypotension During Cesarean Section and Short Term Neonatal Outcome.
NCT00330512
Maternal Lateral Tilt and Cardiac Output in Caesarean Section
NCT05143684
The Feasibility of PetCO2 Prediction Hypotension Under Spinal Anesthesia for Cesarean Section
NCT02032355
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
There are two alternative hypotheses to explain why hypotension might be so commonly diagnosed after regional analgesia during labour: preload reduction theory and afterload reduction theory. A non-invasive continue haemodynamic monitoring could be useful in detecting pregnant women with a positive preoperative supine stress, at increased risk for clinically significant hypotension during Caesarean section under spinal anaesthesia. These women seem more likely to benefit from optimizing the administration of fluids and vasoconstrictors to maintain pressure and cardiac output at basal levels.
Predictors of clinical need of therapy to counteract symptomatic hypotension (dependant variable) will be sought by using regression logistic analysis. Putative variable to include in the model will be selected through clinical and statistical criteria. Univariate screening will be performed assuming the usual cut-off of p\<0,1 and taking into account the biological relevance. The final variable to challenge in the multivariate model will be selected according to the parsimony criteria in order to avoid overfitting and multicollinearity.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Obstetric nulliparous or multiparous patients
* Spontaneous pregnancy
* Single foetus, at term
* Elective Caesarean section, fasting according to international guidelines
* At term BMI \> 18 and \< 35 kg/m2
Exclusion Criteria
* Previous documented maternal cardiovascular problems
* Gestational hypertension (defined as new onset systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg on two occasions at east 4 - 6 hours apart while the patient is on bed rest, with an appropriately sized cuff, after 20 weeks gestation)
* Chronic hypertension of any causes (defined as systemic blood pressure \> 140/90 mmHg)
* Preeclampsia (defined as gestational hypertension with one or more of the following de novo conditions:
* Proteinuria (defined as the excretion of 300 mg or more of protein in a 24-hour urine collection or a protein/creatinine ratio of at least 0.3 (each measured as mg/dL) or at least 1 g/L \[2+\] on dipstick testing)
* Other maternal organ dysfunction:
1. progressive renal insufficiency (renal creatinine concentration greater than 1.1 mg/dL or a doubling of the serum creatinine concentration in the absence of other renal disease),
2. impaired liver function as indicated by abnormally elevated blood concentrations of liver enzymes (at least twice upper limit of normal concentration), severe persistent right upper quadrant or epigastric pain unresponsive to medication and not accounted for by alternative diagnoses, or both),
3. new-onset cerebral or visual disturbances (examples include eclampsia, altered mental status, blindness, stroke, or more commonly hyperreflexia when accompanied by clonus, severe headaches when accompanied by hyperreflexia, persistent visual scotoma),
4. haematological complications (thrombocytopenia - platelet count below 150,000/dL, disseminated intravascular coagulation (DIC), haemolysis).
* Uteroplacental dysfunction with foetal growth restriction (less than fifth percentile)
* Reversed end-diastolic flow on umbilical artery Doppler studies (IR \> 0,5 at 24 week gestation)
18 Years
45 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Papa Giovanni XXIII Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chiara Viviani
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chiara Viviani, M.D.
Role: PRINCIPAL_INVESTIGATOR
ASST Papa Giovanni XXIII, Bergamo, Italy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Asst Papa Giovanni Xxiii
Bergamo, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Reg. 2018/0051
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.